In a complementary vein, Lee et al. have confirmed that RUNX3 serves as an inhibitor of HIF-1α in gastric cancer cells, promoting the prolyl hydroxylation and degradation of HIF-1α through interactions with PHD-2, ultimately suppressing hypoxia-induced angiogenesis within the tumor microenvironment [153]. The gene discussed is HIF1A; the disease is neoplasm.